Overview
William Gaede, whose 2013 Supreme Court patent infringement victory for Ambry Genetics over Myriad Genetics paved the way for the most recent court ruling that refused to block sales of competing hereditary cancer tests, said that Myriad’s initial claims “encompassed laws of nature and the court agreed with us that, given their breadth, they constituted unpatentable subject matter.” Mr. Gaede added that the court did not address Ambry’s arguments that the patents were invalid on other grounds, and that Ambry didn’t infringe them.
